D. Stolz, E. Hermansson, M. Ouwens, B. Singh, A. Sharma, D. Jackson, P. Darken, J. Marshall, H. Müllerová, B. Alcázar Navarrete, R. Russell, M. Han, M. Bafadhel, D. Tansey-Dwyer
{"title":"布地奈德/甘替罗酸酯/富马酸福莫特罗与糠酸氟替卡松/乌莫替尼铵/维兰特罗治疗慢性阻塞性肺病的死亡率风险降低:一项匹配调整的精神和影响的间接比较","authors":"D. Stolz, E. Hermansson, M. Ouwens, B. Singh, A. Sharma, D. Jackson, P. Darken, J. Marshall, H. Müllerová, B. Alcázar Navarrete, R. Russell, M. Han, M. Bafadhel, D. Tansey-Dwyer","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2859","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":205419,"journal":{"name":"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1","volume":"13 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mortality Risk Reduction With Budesonide/Glycopyrrolate/Formoterol Fumarate Versus Fluticasone Furoate/Umeclidinium/Vilanterol in COPD: A Matching-Adjusted Indirect Comparison of Ethos and Impact\",\"authors\":\"D. Stolz, E. Hermansson, M. Ouwens, B. Singh, A. Sharma, D. Jackson, P. Darken, J. Marshall, H. Müllerová, B. Alcázar Navarrete, R. Russell, M. Han, M. Bafadhel, D. Tansey-Dwyer\",\"doi\":\"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2859\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":205419,\"journal\":{\"name\":\"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1\",\"volume\":\"13 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2859\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2859","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Mortality Risk Reduction With Budesonide/Glycopyrrolate/Formoterol Fumarate Versus Fluticasone Furoate/Umeclidinium/Vilanterol in COPD: A Matching-Adjusted Indirect Comparison of Ethos and Impact